Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
4.520
+0.190 (4.39%)
At close: Oct 16, 2026, 4:00 PM EDT
4.584
+0.064 (1.41%)
After-hours: Oct 16, 2026, 7:30 PM EDT
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
36
Market Cap
87.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 881.71K | -3.06M | -77.61% |
| Dec 31, 2020 | 3.94M | -32.21M | -89.11% |
| Dec 31, 2019 | 36.14M | 31.32M | 649.51% |
| Dec 31, 2018 | 4.82M | 2.38M | 97.62% |
| Dec 31, 2017 | 2.44M | 528.77K | 27.66% |
| Dec 31, 2016 | 1.91M | 1.26M | 194.80% |
| Dec 31, 2015 | 648.38K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 63.82M |
| NeurAxis | 5.32M |
| Equillium | 4.39M |
| Kazia Therapeutics | 1.27M |
| Rallybio | 646.00K |
CRBP News
- 18 days ago - Corbus announces first patient dosed in TEMPO-1 study of CRB-701 - TheFly
- 18 days ago - Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - GlobeNewsWire
- 4 weeks ago - Corbus Pharmaceuticals Holdings Transcript: Study result - Transcripts
- 4 weeks ago - Corbus Pharmaceuticals Holdings Press release: Study result - Filings
- 4 weeks ago - Corbus Pharmaceuticals Holdings Slides: Study result - Filings
- 4 weeks ago - Corbus Pharmaceuticals announces topline data from CANYON-1 trial - TheFly
- 4 weeks ago - Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - GlobeNewsWire